Unfortunately, we did not have enough samples to evaluate the prognostic significance of additional alterations (i.e., JAK2 mutations, IKZF1, and CDKN2A/B deletions) in the cohort of 56 B-other ALL patients or within the subgroups of patients with and without CRLF2 overexpression. Here, JAK2 is linked to acute lymphoblastic leukemia.